1 results match your criteria: "Applied Cancer Research Institute for Translational Research VIEnna (ACR-ITR[Affiliation]"
Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients.
Cancer Invest
February 2011
Applied Cancer Research Institute for Translational Research VIEnna (ACR-ITR, VIEnna)/CEADDP, Vienna, Austria.
An adjuvant chemotherapeutic standard has not been identified in triple negative breast cancer (TNBC) yet. One hundred and forty-one adjuvant treated TNBC patients had a median follow-up of 71 months. Larger tumor size (p = .
View Article and Find Full Text PDF